Table 2 Baseline characteristics and univariate analyses of prognostic factors of 69 patients with NPC.

From: The Prognostic Value of Deficient Mismatch Repair in Stage II–IVa Nasopharyngeal Carcinoma in the Era of IMRT

Characteristic

MMR status n (%)

χ2

P value

OS

PFS

LRFS

DMFS

pMMR

dMMR

  

P

P

P

P

Sex

  

1.16

0.28

0.39

0.85

0.77

0.67

Male

25 (71.4)

28 (82.4)

      

Female

10 (28.6)

6 (17.6)

      

Age (years)

  

2.44

0.12

0.07

0.02

0.04

0.04

<53

13 (37.1)

19 (55.9)

      

≥53

22 (62.9)

15 (44.1)

      

Histological pathology typea

  

NA

NA

NA

NA

NA

NA

Type 1

0 (0.0)

0 (0.0)

      

Type 2

35 (100.0)

34 (100.0)

      

Type 3

0 (0.0)

0 (0.0)

      

Clinical stageb

  

0.17

1.00

0.01

0.05

0.50

0.08

II

5 (14.3)

4 (11.8)

      

III

16 (45.7)

16 (47.1)

      

IVa

14 (40.0)

14 (41.2)

      

T-categoryb

  

0.01

0.95

0.02

0.03

0.08

0.04

T1-2

8 (22.9)

8 (23.5)

      

T3-4

27 (77.1)

26 (76.5)

      

N-categoryb

  

0.13

0.71

0.06

0.23

0.21

0.50

N0-2

29 (82.9)

27 (79.4)

      

N3

6 (17.1)

7 (20.6)

      

Therapy regimens

  

0.17

0.92

0.11

0.18

0.45

0.24

IMRT

8 (22.9)

9 (26.5)

      

CCRT

17 (48.6)

15 (44.1)

      

ACCRT

10 (28.6)

10 (29.4)

      

MMR status

  

NA

NA

0.06

0.09

0.95

0.02

pMMR

NA

NA

      

dMMR

NA

NA

      
  1. aWHO Classification of Head and Neck Tumours 4th Edition: type 1, Keratinizing squamous cell carcinoma; type 2, Non-keratinizing squamous cell carcinoma; type 3, Basaliod squamous cell carcinoma; bAccording to the AJCC TNM classification of malignant tumours 8th ed.
  2. Abbreviations: NPC: nasopharyngeal carcinoma; MMR: mismatch repair; dMMR: deficient MMR; pMMR: proficient MMR; OS: overall survival; PFS: progression-free survival; DMFS: distant metastasis-free survival; LRFS: local recurrence-free survival; IMRT: intensity-modulated radiotherapy; CCRT: concurrent chemoradiotherapy; ACCRT: asynchronous combination chemoradiotherapy; NA: Not applicable.